Usage Patterns of Stop Smoking Medications in Australia, Canada, the United Kingdom, and the United States: Findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey
2011

Usage Patterns of Stop Smoking Medications in Four Countries

Sample size: 4032 publication 10 minutes Evidence: moderate

Author Information

Author(s): Brian V. Fix, Andrew Hyland, Cheryl Rivard, Ann McNeill, Geoffrey T. Fong, Ron Borland, David Hammond, K. Michael Cummings

Primary Institution: Roswell Park Cancer Institute

Hypothesis

How has the introduction of varenicline influenced the usage patterns of stop smoking medications in the US, UK, Canada, and Australia?

Conclusion

The introduction of varenicline led to a significant increase in the use of stop smoking medications among smokers attempting to quit.

Supporting Evidence

  • Self-reported use of any stop smoking medication increased significantly over the three-year period.
  • Varenicline became the second most used stop smoking medication in all four countries.
  • Use rates of varenicline increased dramatically in the US, Canada, and Australia, while uptake in the UK was slower.

Takeaway

This study found that more people are using medications to help them stop smoking, especially a new drug called varenicline, which is helping many smokers quit.

Methodology

Data from the ITC Four Country Survey was analyzed, focusing on smokers who reported a quit attempt in the past year across four countries.

Potential Biases

Potential biases may arise from self-reported data on medication use.

Limitations

The sample size of users for specific medications was relatively small, limiting statistical power for some analyses.

Participant Demographics

Participants included smokers from the US, UK, Canada, and Australia, with variations in demographics such as sex, age, ethnicity, income, and education.

Statistical Information

P-Value

p<0.001

Confidence Interval

95%CI: 0.46–0.80

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/ijerph8010222

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication